BrigitteCWidemannMD

Pediatric Hematology & Oncology • Bethesda, MD

Physician

Join to view full profile

Are you Dr. Widemann?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 32 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
8906 Bradmoor Dr
Bethesda, MD 20817
Phone+1 301-496-7387

Fax+1 301-480-8871

Summary

Dr. Brigitte Widemann, MD is a pediatric hematologist/oncologist in Bethesda, Maryland. She is currently licensed to practice medicine in Maryland.

Education & Training

National Capital ConsortiumFellowship, Pediatric Hematology/Oncology, 1992 - 1995
Medizinische Fakultät Universität zu KölnClass of 1988

Certifications & Licensure

MD State Medical License 1999 - 2025

Clinical Trials

Study of Plexiform Neurofibromas in Neurofibromatosis Type 1 Start of enrollment: 2001 May 18
Completed
Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors Start of enrollment: 2001 Feb 15
Completed
Phase 1
Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate Start of enrollment: 1993 Nov 01
Completed
Not Applicable
Tipifarnib in Treating Young Patients With Refractory Leukemia Start of enrollment: 2001 Jun 01
Completed
Phase 1
Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas Start of enrollment: 2002 Dec 01
Completed
Phase 1
Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas Start of enrollment: 2004 Jul 21
Completed
Phase 2
PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma Start of enrollment: 2005 Sep 01
Completed
Phase 1
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors Start of enrollment: 2005 Dec 01
Completed
Phase 2
AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia Start of enrollment: 2006 May 01
Completed
Phase 1
Ixabepilone in Treating Young Patients With Refractory Solid Tumors Start of enrollment: 2006 Apr 01
Completed
Phase 2
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development Start of enrollment: 2004 Sep 07
Completed
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772, IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias Start of enrollment: 2006 May 01
Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer Start of enrollment: 2007 Jul 20
Completed
Phase 1, Phase 2
A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas Start of enrollment: 2008 Mar 01
A Phase II Trial of Peginterferon Alpha-2b (Pegintron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform Neurofibromas Start of enrollment: 2008 May 01
Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas Start of enrollment: 2008 Jul 08
Completed
Phase 1
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 Start of enrollment: 2009 Jul 01
Completed
Phase 2
Natural History Study of Patients With Neurofibromatosis Type I Start of enrollment: 2008 Feb 25
Active, not recruiting
Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas Start of enrollment: 2010 Jul 10
Completed
Phase 2
Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors Start of enrollment: 2010 Dec 03
Completed
Phase 1
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors Start of enrollment: 2011 Sep 21
Active, not recruiting
Phase 1, Phase 2
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia Start of enrollment: 2006 May 30
Completed
Phase 1, Phase 2
Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors Start of enrollment: 2011 Dec 01
Completed
Phase 1
Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma Start of enrollment: 2012 May 10
Terminated
Phase 1, Phase 2
Natural History Study of Children and Adults With Medullary Thyroid Cancer Start of enrollment: 2012 Jul 30
Recruiting
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors Start of enrollment: 2012 Sep 01
Completed
Phase 2
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Start of enrollment: 2012 Nov 14
Completed
Phase 1
Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas Start of enrollment: 2013 May 15
Completed
Phase 2
SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) Start of enrollment: 2013 Dec 01
Completed
Phase 1, Phase 2
Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors Start of enrollment: 2013 Dec 14
Completed
Phase 2
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1 Start of enrollment: 2014 Jun 01
Completed
Phase 2
Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults Start of enrollment: 2014 Jun 01
Completed
Phase 2
VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors Start of enrollment: 2014 Sep 01
Completed
Phase 1
Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Start of enrollment: 2014 Dec 08
Completed
Phase 1
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors Start of enrollment: 2015 Dec 11
Completed
Phase 1
http://clinicaltrials.gov/ct2/show/NCT02644512
Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma Start of enrollment: 2017 Aug 26
Completed
Phase 2
Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST) Start of enrollment: 2017 Apr 07
Withdrawn
Phase 2
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors Start of enrollment: 2019 Oct 02
Completed
Phase 2
SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients Start of enrollment: 2021 Jan 05
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Risk of carcinomas among children and adolescents with birth defects.
Jeremy M Schraw, Ji Yun Tark, Tania A Desrosiers, Tiffany M Chambers, Charles J Shumate
Cancer Epidemiology. 2025-01-22
A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.
Millicent S Curlee, Mary Anne Toledo-Tamula, Melissa Baker, Daniel Wikstrom, Cynthia Harrison
Cancers. 2025-01-17
1 citations
Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial.
Andrea M Gross, Geraldine O'Sullivan Coyne, Eva Dombi, Cecilia Tibery, William G Herrick
Nature Medicine. 2025-01-01

Press Mentions

Faith and Ingenuity: Bringing the First Oncology Clinical Trial to TrinidadJanuary 16th, 2025
NCI Launches Program to Offer Molecular Characterization of Childhood CancersMarch 21st, 2022
IU Researcher Leads National Work Focused on Developing Treatments for Inherited Childhood CancersNovember 18th, 2021
Join now to see all

Grant Support

Development Of Therapies For Neurofibromatosis Type 1 Related Tumors And Other GNational Cancer Institute2010–2011
Clinical Development Of Novel Drugs For Children With Refractory CancersNational Cancer Institute2010–2011
Clinical Development Of Novel Drugs For Children With Refractory CancersDivision Of Clinical Sciences - Nci2009
Development Of Therapies For Neurofibromatosis Type 1 Related Tumors And Other GDivision Of Basic Sciences - Nci2009
Development Of Therapies For Neurofibromatosis Type 1 Related Tumors And Other GNational Cancer Institute2008
Clinical Development Of Novel Drugs For Children With Refractory CancersNational Cancer Institute2007–2008
Clinical Development Of Therapies For Neurofibromatosis Type 1-Related TumorsNational Cancer Institute2007
Clinical Development Of Novel Drugs For Children With CADivision Of Clinical Sciences - Nci2002–2006
Clinical Development Of Drugs For Children With Cancer &Division Of Clinical Sciences - Nci2004
Novel Drugs For Children With Cancer /NeurofibromatosisDivision Of Clinical Sciences - Nci2001
Novel Drugs For Children With Cancer &NeurofibromatosisDivision Of Clinical Sciences - Nci2000

Professional Memberships

American Society of Clinical Oncology - ASCO
Member